Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

Click here to learn how we are responding.

Experience Matters

BeneFIX: For once-weekly prophylaxis (patients ≥16 years old) and on-demand use​​​​​​​2

BeneFIX: Once-weekly prophylactic (for patients ≥16 years old) and on-demand dosing to fit patients’ lifestyles—from the only recombinant factor IX (FIX) supporting individuals with hemophilia B for more than 20 years.​​​​​​​1,2,*

See once-weekly prophylaxis data

Proven bleed control

A breadth of clinical experience—efficacy and safety studied in previously untreated patients (PUPs) and in previously treated patients (PTPs).2

See on-demand data

** This is an optional area where footnotes can live.

Dosing options to meet patients’ needs

Routine prophylaxis (≥16 years old) recommended regimen is 100 IU/kg once weekly, and a wide range of vial sizes is available for on-demand bleed control.2

Learn more about dosing options

** This is an optional area where footnotes can live.

Experience matters

Learn about the clinical history and manufacturing and purification process of BeneFIX.

Read more

** This is an optional area where footnotes can live.

Access

  • Available in hundreds of institutions nationwide3
  • 99% of commercially insured patients have access to BeneFIX​​​​​​​3
See resources and support options

** This is an optional area where footnotes can live.

Financial assistance

Pfizer has a number of financial support resources and programs for your eligible patients.

Learn more

** This is an optional area where footnotes can live.

Stay connected with BeneFIX and Pfizer

Sign up to receive important information about BeneFIX, hemophilia B, and more.

Register now

** This is an optional area where footnotes can live.


References:
  1. ​​​​​​​Center for Biologics Evaluation and Research, US Food and Drug Administration, US Department of Health and Human Services. CBER Approval Letter, Coagulation Factor IX (Recombinant), Genetics Institute, Inc. February 11, 1997. Accessed May 12, 2021. wayback.archive-it.org/7993/20170723024338/https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm057039.htm​​​​​​​
  2. BeneFIX. Prescribing information. Pfizer Inc.; 2021.
  3. Data on file. Pfizer Inc., New York, NY.
  • BeneFIX is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein (CHO).
  • Hypersensitivity reactions, including anaphylaxis, have been reported with BeneFIX. Closely monitor patients for signs and symptoms of acute anaphylaxis, particularly during the early phases of initial exposure to the product. Immediately discontinue the administration of the product and initiate appropriate treatment if symptoms occur.
  • Patients may develop hypersensitivity to hamster protein as BeneFIX contains trace amounts.
  • BeneFIX has been associated with the development of thromboembolic complications, including in patients receiving continuous infusion through a central venous catheter. The safety and efficacy of BeneFIX  administration by continuous infusion have not been established.
  • Neutralizing antibodies (inhibitors) have been reported following the administration of BeneFIX. If expected plasma factor IX activity levels are not attained, or if the patient presents with an allergic reaction, or if bleeding is not controlled following an expected dose of BeneFIX, perform an assay that measures factor IX inhibitor concentration.
  • The most common adverse reactions (>5%) from clinical trials were fever, cough, nausea, injection site reaction, injection site pain, headache, dizziness, and rash.

BeneFIX, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated for the treatment of:

  • Adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for:
    • On-demand treatment and control of bleeding episodes.
    • Perioperative management of bleeding.
  • Patients 16 years of age and older with hemophilia B (congenital factor IX deficiency or Christmas disease) for:
    • Routine prophylaxis to reduce the frequency of bleeding episodes.

Limitation of use:

BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Please see full Prescribing Information for BeneFIX.

Indication

BeneFIX, Coagulation Factor IX (Recombinant), is a human blood coagulation factor indicated for the treatment of:

  • Adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease) for:
    • On-demand treatment and control of bleeding episodes.
    • Perioperative management of bleeding.
  • Patients 16 years of age and older with hemophilia B (congenital factor IX deficiency or Christmas disease) for:
    • Routine prophylaxis to reduce the frequency of bleeding episodes.

Limitation of use:
BeneFIX is not indicated for induction of immune tolerance in patients with hemophilia B.

Please see full Prescribing Information for BeneFIX.